DEG’s support of Finnegan and their client Biogen help win sweeping victory against Mylan over patent dispute regarding best-selling multiple sclerosis drug, Tecfidera

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) gave a favorable ruling to Biogen who holds a market exclusivity in the United States until 2028 on their ’514 patent covering the treatment for multiple sclerosis with 480mg dose of dimethyl fumarate. Tecfidera represents 39% of the company’s total product revenues in 2019, and this victory increases Biogen’s chances of winning generic litigation depending in another court case.

Biogen MS Drug Patent Survives Mylan’s PTAB Challenge – Law360